The Cerebellum

, Volume 18, Issue 2, pp 291–294 | Cite as

Hispanic Spinocerebellar Ataxia Type 35 (SCA35) with a Novel Frameshift Mutation

  • Chih-Chun Lin
  • Shi-Rui Gan
  • Deepak Gupta
  • Armin Alaedini
  • Peter H Green
  • Sheng-Han KuoEmail author
Short Report


Genetic mutations in transglutaminase 6 (TGM6) are recently identified to be associated with spinocerebellar ataxia type 35 (SCA35). We report a Hispanic SCA35 patient, who was confirmed to have a heterozygous, single-nucleotide deletion in TGM6, causing a frameshift mutation with a premature stop codon. An immune-mediated ataxia previously found to be associated with autoantibody reactivity to TG6 may share a similar pathomechanism to SCA35, suggesting a converging role for TG6 in cerebellar function.


Spinocerebellar ataxia SCA35 Gluten Cerebellum Transglutaminase TGM6 


Authors’ Contributions

CCL: examined the patient, reviewed his medical records, searched literature, and wrote the first draft of the manuscript.

SRG: examined the patient, reviewed his medical records, and critically reviewed the manuscript.

DG: examined the patient, reviewed his medical records, and critically reviewed the manuscript.

AA: performed TG6, TG2, and gliadin antibody assays and critically reviewed the manuscript.

PG: examined the patient, performed endoscopy, and critically reviewed the manuscript.

SHK: examined the patient, reviewed his medical records, and critically reviewed the manuscript.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent for videotaping and publishing the video for academic purposes was obtained from the subject reported in this article.


  1. 1.
    Wang JL, Yang X, Xia K, Hu ZM, Weng L, Jin X, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain. 2010;133(Pt 12):3510–8.CrossRefGoogle Scholar
  2. 2.
    Li M, Pang SY, Song Y, Kung MH, Ho SL, Sham PC. Whole exome sequencing identifies a novel mutation in the transglutaminase 6 gene for spinocerebellar ataxia in a Chinese family. Clin Genet. 2013;83(3):269–73.CrossRefGoogle Scholar
  3. 3.
    Folk JE. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol. 1983;54:1–56.Google Scholar
  4. 4.
    Stamnaes J, Dorum S, Fleckenstein B, Aeschlimann D, Sollid LM. Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia. Amino Acids. 2010;39(5):1183–91.CrossRefGoogle Scholar
  5. 5.
    Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, Davies-Jones GA, Gibson A, Jarratt JA, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet. 1998;352(9140):1582–5.CrossRefGoogle Scholar
  6. 6.
    Hadjivassiliou M. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain. 2003;126(3):685–91.CrossRefGoogle Scholar
  7. 7.
    Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grunewald RA. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74(9):1221–4.CrossRefGoogle Scholar
  8. 8.
    Hadjivassiliou M, Aeschlimann P, Sanders DS, Maki M, Kaukinen K, Grunewald RA, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology. 2013;80(19):1740–5.CrossRefGoogle Scholar
  9. 9.
    Harding AE. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the ‘the Drew family of Walworth’. Brain. 1982;105(Pt 1):1–28.CrossRefGoogle Scholar
  10. 10.
    Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol. 2008;64(3):332–43.CrossRefGoogle Scholar
  11. 11.
    Boscolo S, Lorenzon A, Sblattero D, Florian F, Stebel M, Marzari R, et al. Anti transglutaminase antibodies cause ataxia in mice. PLoS One. 2010;5(3):e9698.CrossRefGoogle Scholar
  12. 12.
    Guo YC, Lin JJ, Liao YC, Tsai PC, Lee YC, Soong BW. Spinocerebellar ataxia 35: novel mutations in TGM6 with clinical and genetic characterization. Neurology. 2014;83(17):1554–61.CrossRefGoogle Scholar
  13. 13.
    Tripathy D, Vignoli B, Ramesh N, Polanco MJ, Coutelier M, Stephen CD, et al. Mutations in TGM6 induce the unfolded protein response in SCA35. Hum Mol Genet. 2017;26(19):3749–62.CrossRefGoogle Scholar
  14. 14.
    Yang ZH, Shi MM, Liu YT, Wang YL, Luo HY, Wang ZL, et al. TGM6 gene mutations in undiagnosed cerebellar ataxia patients. Parkinsonism Relat Disord. 2018;46:84–6.CrossRefGoogle Scholar
  15. 15.
    Guan WJ, Wang JL, Liu YT, Ma YT, Zhou Y, Jiang H, et al. Spinocerebellar ataxia type 35 (SCA35)-associated transglutaminase 6 mutants sensitize cells to apoptosis. Biochem Biophys Res Commun. 2013;430(2):780–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Chih-Chun Lin
    • 1
  • Shi-Rui Gan
    • 2
  • Deepak Gupta
    • 3
  • Armin Alaedini
    • 4
    • 5
  • Peter H Green
    • 4
    • 5
  • Sheng-Han Kuo
    • 3
    Email author
  1. 1.Methodist Neurological InstituteHoustonUSA
  2. 2.Department of Neurology and Institute of NeurologyThe First Affiliated Hospital of Fujian Medical UniversityFujianChina
  3. 3.Department of NeurologyColumbia University Medical CenterNew YorkUSA
  4. 4.Department of MedicineColumbia University Medical CenterNew YorkUSA
  5. 5.Celiac Disease Center, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations